搜尋結果
Paris – June 13, 2022 – Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with its new next-generation COVID-19 booster vaccine candidate modelled on the Beta variant antigen and including GSK’s pandemic adjuvant.
Sanofi expects to launch the new Primary Care and China & Emerging Markets global business units by the beginning of 2019. Sanofi’s other GBUs—Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare—remain unchanged. About Dieter Weinand A U
SANOFI san-2362 Lantus Solorstar guide R02 Size:21 Omm(W)x297mm(H) 24-Hour LANTUS insulin glargne unwmL BI-antus@ Solostar@ , 5541 5070 Reference: Lantus. Package Insert (852) 2506 8333 (852) 2506 2537 00 SANOFI O Created Date 11/30/2020 ...
Sanofi's global vaccines business unit partners with the public health, medical and scientific communities to improve access to life-protecting vaccines and increase vaccination coverage, while striving to develop new and improved vaccines to enhance health and ...
Dupixent was designed to inhibit signaling from two important proteins (IL-4 and IL-13) involved in Type 2 inflammation that contribute to uncontrolled symptoms in many people with moderate-to-severe asthma.” The QUEST trial enrolled 1,902 patients worldwide including 1,795 adults and 107 adolescents.
Sanofi Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com Regeneron Investor Relations Contact Manisha Narasimhan, Ph.D. Tel: +1 (914) 847-5126 manisha.narasimhan@regeneron.com Sanofi Forward-Looking Statements
Paris – September 3, 2018 – The European Commission has granted marketing authorization for CabliviTM (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated for the treatment of aTTP.
